\-\ Texto\\:\\ \ \(0\)\
\-\ the\\ patinet\\ is\\ a\\ cachectic\\,\\ jaundiced\\,\\ elderly\\ asian\\ female\\.\\ serum\\ total\\ bilirubin\\ 14\\.9mg\\/dl\\,\\ alkaline\\ phosphatase\\ 956\\ u\\/l\\.\ \(0\)\
\-\ \\>\\>\\ treatment\\ for\\ advanced\\ disease\\ usually\\ includes\\ chemotherapy\\ \\(traditionally\\ chop\\ although\\ this\\ is\\ evolving\\ and\\ has\\ changed\\ significantly\\ over\\ the\\ last\\ 30\\ years\\)\\.\\ \ \(0\)\
\-\ \\>\\>\\ other\\ interventions\\ are\\ usually\\ palliative\\,\\ as\\ in\\ this\\ case\\ where\\ percutaneous\\ biliary\\ drainage\\ followed\\ by\\ endobiliary\\ stenting\\ with\\ internal\\ drainage\\ was\\ performed\\.\ \(0\)\
\-\ \\>\\>\\ ct\\ liver\\:\\ infiltrative\\ mass\\ in\\ right\\ lobe\\ of\\ liver\\,\\ intrahepatic\\ biliary\\ dilatation\\,\\ lymphadenopathy\\.\ \(0\)\
\-\ \\>\\>\\ percutaneous\\ cholangiogram\\ and\\ external\\ biliary\\ drain\\ placement\\:\\ mildly\\ dilated\\ intrahepatic\\ biliary\\ ducts\\,\\ mass\\ effect\\ displaces\\ common\\ hepatic\\ duct\\.\ \(0\)\
\-\ \\>\\>\\ percutaneous\\ cholangiogram\\ and\\ endobiliary\\ stent\\ placement\\:\\ gore\\ viabil\\ covered\\ metallic\\ stent\\ allows\\ internal\\ drainage\\.\ \(0\)\
\-\ large\\ b\\ cell\\ lymphoma\\ of\\ the\\ liver\\ with\\ malignant\\ biliary\\ obstruction\ \(0\)\
\-\ \\>\\>\\ hepatocellular\\ carcinoma\ \(0\)\
\-\ \\>\\>\\ cholangiocarcinoma\ \(0\)\
\-\ one\\ month\\ of\\ abdominal\\ pain\\,\\ nausea\\,\\ and\\ vomiting\\.\ \(0\)\
\-\ key\\ facts\\ for\\ biliary\\ stenting\\ of\\ malignant\\ obstructive\\ jaundice\\:\ \(0\)\
\-\ \\>\\>\\ it\\ is\\ palliative\\ therapy\\.\ \(0\)\
\-\ \\>\\>\\ metal\\ stents\\ demonstrate\\ longer\\ patency\\ than\\ plastic\\ \\(polyethylene\\)\\ stents\\ for\\ malignant\\ biliary\\ obstruction\\ \\(median\\ expected\\ patency\\:\\ 250\\ and\\ 110\\ days\\ respectively\\)\\.\ \(0\)\
\-\ \\>\\>\\ this\\ treatment\\ provides\\ significant\\ palliation\\ of\\ patient\\ symptoms\\ due\\ to\\ biliary\\ obstruction\\ and\\ is\\ cost\\-effective\\ in\\ patients\\ with\\ longer\\ than\\ 6\\ months\\ expected\\ survival\\ resulting\\ in\\ fewer\\ hospital\\ admissions\\.\ \(0\)\
\-\ \\>\\>\\ covered\\ endobiliary\\ stents\\ like\\ the\\ gore\\ viabil\\ used\\ in\\ this\\ case\\ have\\ good\\ patency\\ rates\\ in\\ malignant\\ biliary\\ obstruction\\ and\\ allow\\ endobiliary\\ drainage\\ into\\ the\\ small\\ bowel\\ which\\ is\\ desirable\\ for\\ outpatient\\ management\\ of\\ these\\ patients\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ biliary\\:\\ 0\\.4470216785439511\ \(0\)\
\-\ endobiliary\\:\\ 0\\.34165773706732533\ \(0\)\
\-\ stents\\:\\ 0\\.1978336759219717\ \(0\)\
\-\ patency\\:\\ 0\\.19300655807091843\ \(0\)\
\-\ drainage\\:\\ 0\\.17110537496582404\ \(0\)\
\-\ viabil\\:\\ 0\\.17082886853366266\ \(0\)\
\-\ gore\\:\\ 0\\.15784895144954658\ \(0\)\
\-\ percutaneous\\:\\ 0\\.15443885322472464\ \(0\)\
\-\ malignant\\:\\ 0\\.15229059210595333\ \(0\)\
\-\ obstruction\\:\\ 0\\.1496431035398913\ \(0\)\
\-\ cholangiogram\\:\\ 0\\.14736955150378592\ \(0\)\
\-\ covered\\:\\ 0\\.12509332650329683\ \(0\)\
\-\ stenting\\:\\ 0\\.12209074009539715\ \(0\)\
\-\ palliative\\:\\ 0\\.11520470306074365\ \(0\)\
\-\ intrahepatic\\:\\ 0\\.11211340941918074\ \(0\)\
\-\ liver\\:\\ 0\\.11053434040795942\ \(0\)\
\-\ longer\\:\\ 0\\.10876721590277962\ \(0\)\
\-\ stent\\:\\ 0\\.1077726780206951\ \(0\)\
\-\ expected\\:\\ 0\\.096305103108986\ \(0\)\
\-\ polyethylene\\:\\ 0\\.08541443426683133\ \(0\)\
\-\ placement\\:\\ 0\\.08341289607753245\ \(0\)\
\-\ patinet\\:\\ 0\\.08161805188849244\ \(0\)\
\-\ 956\\:\\ 0\\.08161805188849244\ \(0\)\
\-\ facts\\:\\ 0\\.08161805188849244\ \(0\)\
\-\ in\\:\\ 0\\.07972025017229896\ \(0\)\
\-\ admissions\\:\\ 0\\.07892447572477329\ \(0\)\
\-\ and\\:\\ 0\\.07725585438688057\ \(0\)\
\-\ desirable\\:\\ 0\\.0751280933464344\ \(0\)\
\-\ this\\:\\ 0\\.07341073773868102\ \(0\)\
\-\ is\\:\\ 0\\.07313364253337921\ \(0\)\
\-\ internal\\:\\ 0\\.07199056613744485\ \(0\)\
\-\ cachectic\\:\\ 0\\.0713317109680955\ \(0\)\
\-\ chop\\:\\ 0\\.0713317109680955\ \(0\)\
\-\ palliation\\:\\ 0\\.0713317109680955\ \(0\)\
\-\ jaundiced\\:\\ 0\\.07034521719337256\ \(0\)\
\-\ fewer\\:\\ 0\\.07034521719337256\ \(0\)\
\-\ traditionally\\:\\ 0\\.06863813480437636\ \(0\)\
\-\ evolving\\:\\ 0\\.06788869245076876\ \(0\)\
\-\ usually\\:\\ 0\\.06724731849623336\ \(0\)\
\-\ for\\:\\ 0\\.06475280879538886\ \(0\)\
\-\ 250\\:\\ 0\\.06433551935697282\ \(0\)\
\-\ plastic\\:\\ 0\\.06339843483149601\ \(0\)\
\-\ of\\:\\ 0\\.06271276281064724\ \(0\)\
\-\ interventions\\:\\ 0\\.062148176262318326\ \(0\)\
\-\ phosphatase\\:\\ 0\\.06139873390871072\ \(0\)\
\-\ metal\\:\\ 0\\.06139873390871072\ \(0\)\
\-\ asian\\:\\ 0\\.061045370047698576\ \(0\)\
\-\ than\\:\\ 0\\.06055337472599648\ \(0\)\
\-\ patients\\:\\ 0\\.06009224456319587\ \(0\)\
\-\ alkaline\\:\\ 0\\.060058876272975625\ \(0\)\
\-\ changed\\:\\ 0\\.05975186414526167\ \(0\)\
\-\ cholangiocarcinoma\\:\\ 0\\.059454600098599195\ \(0\)\
\-\ displaces\\:\\ 0\\.05888696988491389\ \(0\)\
\-\ provides\\:\\ 0\\.058615558678434175\ \(0\)\
\-\ allow\\:\\ 0\\.058615558678434175\ \(0\)\
\-\ allows\\:\\ 0\\.05835179388397944\ \(0\)\
\-\ bilirubin\\:\\ 0\\.05736530010925649\ \(0\)\
\-\ jaundice\\:\\ 0\\.05690847628943798\ \(0\)\
\-\ metallic\\:\\ 0\\.056472907940732515\ \(0\)\
\-\ elderly\\:\\ 0\\.05626249389463672\ \(0\)\
\-\ key\\:\\ 0\\.05626249389463672\ \(0\)\
\-\ 110\\:\\ 0\\.05605670470959037\ \(0\)\
\-\ rates\\:\\ 0\\.05565821772026029\ \(0\)\
\-\ median\\:\\ 0\\.05527600011991378\ \(0\)\
\-\ respectively\\:\\ 0\\.05527600011991378\ \(0\)\
\-\ ducts\\:\\ 0\\.05509058750657499\ \(0\)\
\-\ hepatocellular\\:\\ 0\\.05490877536665269\ \(0\)\
\-\ infiltrative\\:\\ 0\\.05473042652656799\ \(0\)\
\-\ outpatient\\:\\ 0\\.05473042652656799\ \(0\)\
\-\ case\\:\\ 0\\.05366534269192615\ \(0\)\
\-\ the\\:\\ 0\\.05328628676776251\ \(0\)\
\-\ drain\\:\\ 0\\.05326190560320363\ \(0\)\
\-\ survival\\:\\ 0\\.05212560013637614\ \(0\)\
\-\ treatment\\:\\ 0\\.050884163250581975\ \(0\)\
\-\ advanced\\:\\ 0\\.050198200970584\ \(0\)\
\-\ significantly\\:\\ 0\\.050198200970584\ \(0\)\
\-\ obstructive\\:\\ 0\\.04966907539377234\ \(0\)\
\-\ serum\\:\\ 0\\.04789364940933177\ \(0\)\
\-\ duct\\:\\ 0\\.04597615297423979\ \(0\)\
\-\ resulting\\:\\ 0\\.04444408560617105\ \(0\)\
\-\ total\\:\\ 0\\.04376283751617895\ \(0\)\
\-\ dilatation\\:\\ 0\\.04359999808995061\ \(0\)\
\-\ last\\:\\ 0\\.04343994238040822\ \(0\)\
\-\ good\\:\\ 0\\.04343994238040822\ \(0\)\
\-\ lymphadenopathy\\:\\ 0\\.0431791168517143\ \(0\)\
\-\ external\\:\\ 0\\.0431791168517143\ \(0\)\
\-\ mildly\\:\\ 0\\.04312781244387365\ \(0\)\
\-\ hepatic\\:\\ 0\\.04253313445691304\ \(0\)\
\-\ where\\:\\ 0\\.041973981410854545\ \(0\)\
\-\ includes\\:\\ 0\\.04153224708826525\ \(0\)\
\-\ nausea\\:\\ 0\\.0410282852213959\ \(0\)\
\-\ mass\\:\\ 0\\.04080249201749463\ \(0\)\
\-\ used\\:\\ 0\\.03998472447242509\ \(0\)\
\-\ like\\:\\ 0\\.039696608478277544\ \(0\)\
\-\ vomiting\\:\\ 0\\.039520936702115074\ \(0\)\
\-\ hospital\\:\\ 0\\.039451580599768644\ \(0\)\
\-\ management\\:\\ 0\\.039451580599768644\ \(0\)\
\-\ dilated\\:\\ 0\\.038253290883736094\ \(0\)\
\-\ chemotherapy\\:\\ 0\\.03792472976836481\ \(0\)\
\-\ effect\\:\\ 0\\.03746650837693325\ \(0\)\
\-\ 30\\:\\ 0\\.0364354021008731\ \(0\)\
\-\ although\\:\\ 0\\.03636059719428498\ \(0\)\
\-\ followed\\:\\ 0\\.03606721451857068\ \(0\)\
\-\ bowel\\:\\ 0\\.03427626564814944\ \(0\)\
\-\ days\\:\\ 0\\.03381092611059594\ \(0\)\
\-\ years\\:\\ 0\\.03273969844531707\ \(0\)\
\-\ month\\:\\ 0\\.03249000282105907\ \(0\)\
\-\ carcinoma\\:\\ 0\\.031947529055917134\ \(0\)\
\-\ lymphoma\\:\\ 0\\.03180904291743503\ \(0\)\
\-\ performed\\:\\ 0\\.03159761065253511\ \(0\)\
\-\ with\\:\\ 0\\.031375116835741484\ \(0\)\
\-\ months\\:\\ 0\\.031089020028125202\ \(0\)\
\-\ lobe\\:\\ 0\\.030865414630943444\ \(0\)\
\-\ significant\\:\\ 0\\.030837835727339034\ \(0\)\
\-\ due\\:\\ 0\\.030701146715734658\ \(0\)\
\-\ therapy\\:\\ 0\\.030687586929144254\ \(0\)\
\-\ one\\:\\ 0\\.03057980984265894\ \(0\)\
\-\ cell\\:\\ 0\\.03055305830730574\ \(0\)\
\-\ common\\:\\ 0\\.030289664539024666\ \(0\)\
\-\ these\\:\\ 0\\.03016069513072459\ \(0\)\
\-\ over\\:\\ 0\\.029698383552028154\ \(0\)\
\-\ symptoms\\:\\ 0\\.02922300069540135\ \(0\)\
\-\ abdominal\\:\\ 0\\.029211419950567898\ \(0\)\
\-\ into\\:\\ 0\\.0283919086440491\ \(0\)\
\-\ demonstrate\\:\\ 0\\.027766449132573014\ \(0\)\
\-\ other\\:\\ 0\\.027736740918318018\ \(0\)\
\-\ small\\:\\ 0\\.027550746732197012\ \(0\)\
\-\ it\\:\\ 0\\.027339901914736137\ \(0\)\
\-\ large\\:\\ 0\\.026761129213713913\ \(0\)\
\-\ have\\:\\ 0\\.026681292368993137\ \(0\)\
\-\ female\\:\\ 0\\.02577285387091325\ \(0\)\
\-\ has\\:\\ 0\\.024396193707560365\ \(0\)\
\-\ which\\:\\ 0\\.024286120069456196\ \(0\)\
\-\ by\\:\\ 0\\.022681041230392423\ \(0\)\
\-\ disease\\:\\ 0\\.022419677520962817\ \(0\)\
\-\ as\\:\\ 0\\.0214567470220339\ \(0\)\
\-\ ct\\:\\ 0\\.02033374008543761\ \(0\)\
\-\ are\\:\\ 0\\.02026671738690881\ \(0\)\
\-\ pain\\:\\ 0\\.01911211208575304\ \(0\)\
\-\ was\\:\\ 0\\.018613961046542133\ \(0\)\
\-\ right\\:\\ 0\\.01770766984502818\ \(0\)\
\-\ patient\\:\\ 0\\.017371635865686238\ \(0\)\
\-\ to\\:\\ 0\\.013352428989884207\ \(0\)\
